Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997 by Delles, Christian et al.
European Journal of Heart Failure (2017) RESEARCH ARTICLE
doi:10.1002/ejhf.1076
Nuclear magnetic resonance-based
metabolomics identifies phenylalanine
as a novel predictor of incident heart failure
hospitalisation: results from PROSPER
and FINRISK 1997
Christian Delles1†, Naomi J. Rankin1,2*†, Charles Boachie3, Alex McConnachie3,
Ian Ford3, Antti Kangas4, Pasi Soininen4,5, Stella Trompet6, Simon P. Mooijaart6,
J. Wouter Jukema6, Faiez Zannad7,8, Mika Ala-Korpela4,5,9,10,11,12, Veikko Salomaa13,
Aki S. Havulinna13,14, Paul Welsh1, Peter Würtz15, and Naveed Sattar1
1Institute of Cardiovascular and Medical Sciences (ICAMS), BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; 2Glasgow Polyomics, Joseph
Black Building, University of Glasgow, Glasgow, UK; 3Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow, Glasgow, UK; 4Computational Medicine,
Faculty of Medicine and Biocenter Oulu, University of Oulu, Oulu, Finland; 5NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland;
6Leiden University Medical Centre, Leiden, The Netherlands; 7Inserm Centre d’Investigation Clinique (CIC) 1443, Université de Lorraine, Lorraine, France; 8Centre Hospitalier
Régional Universitaire (CHRU) de Nancy, Nancy, France; 9Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK; 10Population Health Science,
Bristol Medical School, University of Bristol, Bristol, UK; 11Systems Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; 12Department of
Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, The Alfred Hospital, Monash
University, Melbourne, Victoria, Australia; 13National Institute for Health and Welfare (THL), Helsinki, Finland; 14Institute for Molecular Medicine (FIMM), University of Helsinki,
Helsinki, Finland; and 15Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland
Received 1 October 2017; revised 5 October 2017; accepted 11 October 2017
Aims We investigated the association between quantified metabolite, lipid and lipoprotein measures and incident heart
failure hospitalisation (HFH) in the elderly, and examined whether circulating metabolic measures improve HFH
prediction.
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Methods
and results
Overall, 80 metabolic measures from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial
were measured by proton nuclear magnetic resonance spectroscopy (n= 5341; 182 HFH events during 2.7-year
follow-up). We repeated the work in FINRISK 1997 (n= 7330; 133 HFH events during 5-year follow-up). In
PROSPER, the circulating concentrations of 13 metabolic measures were found to be significantly different in those
who were later hospitalised for heart failure after correction for multiple comparisons. These included creatinine,
phenylalanine, glycoprotein acetyls, 3-hydroxybutyrate, and various high-density lipoprotein measures. In Cox models,
two metabolites were associated with risk of HFH after adjustment for clinical risk factors and N-terminal pro-B-type
natriuretic peptide (NT-proBNP): phenylalanine [hazard ratio (HR) 1.29, 95% confidence interval (CI) 1.10–1.53;
P= 0.002] and acetate (HR 0.81, 95% CI 0.68–0.98; P= 0.026). Both were retained in the final model after backward
elimination. Compared to a model with established risk factors and NT-proBNP, this model did not improve the
C-index but did improve the overall continuous net reclassification index (NRI 0.21; 95% CI 0.06–0.35; P= 0.007) due
to improvement in classification of non-cases (NRI 0.14; 95% CI 0.12–0.17; P< 0.001). Phenylalanine was replicated
as a predictor of HFH in FINRISK 1997 (HR 1.23, 95% CI 1.03–1.48; P= 0.023).
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Conclusion Our findings identify phenylalanine as a novel predictor of incident HFH, although prediction gains are low. Further
mechanistic studies appear warranted.
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Introduction
The prevention of heart failure (HF) is an important clinical issue.
Patients with HF have a high mortality and impaired quality of life,
so identifying those at risk is important.1,2 The risk of HF increases
with age but typical symptoms of HF, such as shortness of breath,
may be absent in the elderly (or masked by other co-morbidities);
the prognosis of HF is poor, and the mechanisms of HF differ in the
elderly.3 Treatment of hypertension and dyslipidaemia, prevention
of diabetes, smoking cessation, increased exercise, weight reduc-
tion, and reduced alcohol intake have been associated with lower
risks for HF.4–6 At present, symptomatic patients have B-type natri-
uretic peptide (BNP) or N-terminal proBNP (NT-proBNP) con-
centrations measured as a rule-out test for HF, a cost-effective
strategy to increase the positive predictive value of echocardio-
graphy. However, routine screening for this marker as part of car-
diovascular disease (CVD) risk screening is not cost-effective as the
assay is currently much more expensive than other routine clinical
laboratory tests.7 More effective screening for prevalent HF, per-
haps using ‘omics technologies, in combination with more effective
interventions, has been described as an urgent need in the HF clin-
ical arena.7 Such strategies might help pave the way toward better
identification of HF, or identify novel treatment strategies. Studies
to improve the understanding of HF aetiology and generate new
hypothesis, particularly in the elderly, are also needed.
Metabolomics is the study of the small molecule complement
of a system using a variety of methods, mainly mass spectrom-
etry (MS) and proton nuclear magnetic resonance (1H-NMR)
spectroscopy.8 Both methods are complementary, each with their
own strengths and limitations.8 MS metabolomics methods are
generally very sensitive, detecting thousands of metabolites, but
routinely provide only relative (rather than absolute) quantitation.
Generally, 1H-NMR metabolomics methods have poor sensitivity
in comparison to MS but do provide absolute quantitation, higher
throughput (resulting in reduced costs), and better reproducibil-
ity. Metabolomics is of particular interest, since HF is strongly
linked to metabolic dysfunction. Dysregulation of cardiac energy
metabolism and cardiac remodelling are key features of HF that
may result in changes in circulating metabolite concentrations,
and adverse metabolic states like diabetes increase HF risk.9–11
Whether changes in metabolic profile precede incident HF is
therefore an important mechanistic line of research. Metabolomics
has been used to study prevalent HF,9,10,12–20 but most stud-
ies have been cross-sectional in nature. Presently, only one study
has prospectively investigated the association of the metabolome
with future HF risk.13 This study used an untargeted gas chro-
matography/MS metabolomics method to identify two metabo-
lites associated with incident HF.13 In contrast, we here employ
a 1H-NMR spectroscopy method that allowed detailed lipopro-
tein subclass analysis, in addition to small molecule and lipid
concentrations,21 to study samples from the PROspective Study of
Pravastatin in the Elderly at Risk (PROSPER) trial.22 We hypoth-
esised that metabolites, lipids and lipoproteins would associate
with HF hospitalisation (HFH) in elderly men and women and
improve HFH prediction beyond established clinical predictors and
NT-proBNP. ..
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Study cohort: PROSPER
The PROSPER trial design has been published.22 In brief, this was
a double-blind, randomised, placebo-controlled trial investigating the
benefit of pravastatin (40mg/day) in elderly individuals at risk of CVD.
Participants were identified in the primary care setting from three
centres: Glasgow, Scotland; Cork, Ireland; and Leiden, The Nether-
lands. Overall, 5804 elderly adults (70–82 years old) were enrolled.
All participants had high-normal to high cholesterol concentrations
(4.0–9.0mmol/L) at baseline. Additionally, 50% of patients had evi-
dence of vascular disease (physician diagnosed stable angina, stroke,
transient ischaemic attack, or myocardial infarction) and the remain-
ing 50% of patients had high risk of vascular disease as they had
either hypertension, diabetes, or were smokers. Individuals with con-
gestive HF [New York Heart Association (NYHA) class III and IV] were
excluded. The primary outcome measure of PROSPER was a compos-
ite CVD outcome. In the current study, the endpoint of interest was
hospitalisation for incident HF. This was defined based on a combina-
tion of symptoms (e.g. shortness of breath) and signs, including chest
radiograph with fluid congestion or echocardiogram with severely
diminished left ventricular function.23 Patients were recruited between
December 1997 and May 1999, and the mean follow-up period was
3.2 years.24 The investigation conforms with the principles outlined in
the Declaration of Helsinki. The institutional ethics review boards of
all three European centres approved the study protocol.25 All partic-
ipants provided written informed consent to participate in the study
and for long-term follow-up.
Fasting venous blood samples were collected at baseline and at
3-month intervals and biobanked at –80 ∘C. For the present study,
previously unthawed 6-month post-randomisation samples were used,
employing the study as a cohort study and adjusting for randomised
treatment in analysis. Overall, 5341 samples were available for this
study, having sample available for 1H-NMR analysis and available
6-month NT-proBNP and other measurements24 (Figure 1). Estimated
glomerular filtration rate (eGFR) was calculated based on routinely
available creatinine, using the Modification of Diet in Renal Disease
(MDRD) equation.26 Eighteen participants who had died or experi-
enced HFH in the first 6months of follow-up were excluded from the
analysis since 6-month samples were used as predictors of incident
HFH.
External replication cohort: FINRISK
The population-based FINRISK 1997 cohort was used as an external
replication cohort. Participants were aged between 25 and 74 years
at recruitment and were derived from the general population in
five study areas across Finland.27 All participants provided written
informed consent and the study protocol was approved by the local
ethics committees. A total of 8444 individuals were recruited and
NMR metabolic measures were available for 7602 baseline serum
samples. Semi-fasting venous blood samples were biobanked at –80 ∘C.
For the present study, samples with only one previous freeze–thaw
cycle were used. Incident HF during follow-up was identified through
the Finnish National Hospital Discharge Register and Cause-of-Death
Register using the International Classification of Diseases diagnosis
codes, 10th revision. Additionally, nationwide drug reimbursement
and prescription registers were used to identify individuals on HF
medication. This method of registry follow-up has been validated.27 We
curtailed follow-up to 5 years (longer than the 2.7 years in PROSPER)
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Flow diagram of the PROSPER study. Of the 5432 samples with 6-month demographic records, including N-terminal pro-B-type
natriuretic peptide (NT-proBNP), 5341 had 6-month sample analysed by nuclear magnetic resonance (NMR) spectroscopy. Of these samples,
182 were from individuals who were later hospitalised for heart failure (HF). 160 samples were excluded due to missing metabolic measures.
Of these 5181, 178 were later hospitalised for HF. HFH, heart failure hospitalisation.
since this is a younger, healthier, cohort. Any individual with prior
HF was excluded, leaving 7330 individuals included in this study. Of
these, 133 individuals were classed as having an incident HF event
within 5 years of follow-up. Estimated GFR was calculated using NMR
measured creatinine concentrations and the MDRD equation as above.
Metabolite, lipid and lipoprotein
quantification
Circulating metabolic measures were quantified using high-throughput
serum NMR metabolomics (Brainshake Ltd, Helsinki, Finland) as pre-
viously described.21,28,29 The quantified metabolite measures are as
described by Soininen et al.21 This includes various metabolites (e.g.
amino acids and creatinine) and extracted lipids (e.g. sphingomyelin and
omega-6 fatty acids). The lipoprotein measures include particle concen-
trations for 14 lipoprotein subclasses, as well as their lipid (total lipid,
free cholesterol, cholesterol ester, phospholipid, and triglyceride) con-
tent. A total of 233 measures were reported. Only 80 metabolite, lipid
or lipoprotein measures were included in the analysis since the majority
of the lipoprotein measures were excluded due to redundancy (over-
lapping nature) of many of the lipoprotein measures. Ratios were also
excluded, with the exception of the fatty acids where normalisation to .
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.. total fatty acids allows more meaningful biological interpretation. The
same NMR platform was used for metabolic profiling of serum samples
from the FINRISK 1997 cohort.
Statistical analysis
All metabolite concentrations were log transformed prior to analysis to
obtain approximately normal distributions. The metabolite measures
were subsequently centred and scaled to standard deviation (SD) units.
Mean imputation of missing continuous baseline characteristics (e.g.
eGFR or total cholesterol) was carried out. For categorical variables
either 3-month or baseline values replaced the missing 6-month values.
Measured metabolite or lipoprotein concentrations denoted zero, as
reported by NMR spectroscopy, were imputed as half of the minimum
reported value. All observations with any NMR measure reported as
‘not available’ were excluded from the analysis of hazard ratios (HR)
and later statistical analysis.
An analysis comparing metabolite or lipoprotein particle concentra-
tions between participants, split by HFH outcome status, was carried
out using the t-test, and the method of Benjamini and Hochberg was
used to control for multiple testing.30 P-values were adjusted using a
false discovery rate (q) of 0.1, raw P-values of ≤0.014 were considered
significant.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Survival analysis was carried out using Cox proportional hazards
regression and the proportional hazards assumption was verified by
the inclusion of time-dependent covariates in the model. Metabolite
and lipoprotein associations were adjusted for treatment group, age,
sex, smoking status, country, body mass index (BMI), systolic blood
pressure (SBP), diastolic blood pressure (DBP), eGFR, NT-proBNP,
history of myocardial infarction, coronary artery bypass graft, percu-
taneous transluminal coronary angioplasty, transient ischaemic attack,
stroke, diabetes mellitus, angina, claudication, peripheral vascular dis-
ease, treatment with angiotensin-converting enzyme (ACE) inhibitors,
beta-blockers, calcium channel blockers, anti-arrhythmic drugs, and/or
diuretics. Medications are as recorded at baseline (first visit) whereas
all other measures were as recorded at 6months. A competing risk
model was also performed, which did not alter the HRs obtained. In
the FINRISK 1997 cohort, Cox models were adjusted for sex, prior
major coronary event (including CVD and revascularisation), BMI, SBP,
DBP, NT-proBNP, smoking, diabetes mellitus, lipid-lowering and blood
pressure-lowering therapy. Age was used as the time-scale.
For risk prediction analysis in PROSPER, NMR-derived metabolic
measures associated with HFH at the P≤ 0.1 significance level were
re-introduced into a model containing classical risk factors using a
backward selection method to identify the metabolites independently
associated with HF.
The established risk factors (Model 1) and the established risk
factors with significant metabolite/lipoprotein measures (Model 2)
were then used in risk prediction analysis by comparing the 2.7-year
predictive risk of HFH between the two models. The C-index and
95% confidence intervals (CIs) were calculated, using bootstrapping for
1000 runs for both point estimates and 95% CIs. The gain in predictive
ability of Model 2 over Model 1 was calculated using bootstrapping.
Net reclassification comparing Model 2 with Model 1was also assessed
using both continuous and categorical risk intervals of <2.5%, ≥2.5 to
<5%, and ≥5%.
Results
Baseline characteristics in PROSPER
In PROSPER, 182 participants out of 5341 were hospitalised with
incident HF during follow-up (3.4%) (Figure 1). Patients hospitalised
with incident HF were older; more likely to be male; more likely to
be recruited in Scotland or Ireland; more likely to have had a pre-
vious myocardial infarction, angina, or claudication; more likely to
have been on ACE inhibitors or anti-arrhythmic therapy at baseline;
and had lower eGFR, lower DBP, and raised NT-proBNP (Table 1).
Associations of metabolites
and lipoprotein measures with heart
failure in PROSPER
Eighteen out of 80 metabolic measures (as quantified by NMR)
were associated with HFH, with P-values of <0.05. After correc-
tion for false discovery rate (Benjamini and Hochberg method),
13 measures were considered statistically significant (raw P-value
of ≤0.014). Distributions of the concentrations of the metabolites
and lipoprotein measures stratified by HFH status are shown in
Table 2 for measures with raw P-values of <0.05 and in the supple-
mentary material online, Table S1, for measures with raw P-values ..
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.. of >0.05. Three of the markers associated with HFH were small
molecules: phenylalanine, creatinine, and 3-hydroxybutyrate; and
one was a measure of glycoprotein acetyls, from highly glycosylated
acute phase proteins.31 All four measures were positively associ-
ated with HFH. Nine were lipoprotein related measures such as
mean low-density lipoprotein (LDL) diameter: all were negatively
associated with HFH. Of these, six were specifically related to
high-density lipoprotein (HDL) particles (apolipoprotein A1), con-
centration of medium HDL particles, concentration of small HDL
particles, total cholesterol content of HDL, and phospholipid con-
tent of HDL. Routine lipid measures such as LDL-cholesterol or
HDL-cholesterol were not associated with incident HFH risk.23,32
In multivariable models adjusting for classical risk factors and
NT-proBNP, phenylalanine had the strongest association with HFH
(HR 1.29 for one SD higher phenylalanine level, 95% CI 1.10–1.53;
P= 0.002) (Figure 2 shows measures with P< 0.05; the supple-
mentary material online, Table S2, for all). Acetate was inversely
associated with HFH (HR 0.81 for one SD higher acetate, 95% CI
0.68–0.98; P= 0.026). A competing risk model was also performed,
which did not alter the HRs obtained.
Multivariable models for risk prediction
In a backward selection procedure (Model 2, including established
risk factors), phenylalanine and acetate were retained as signifi-
cant predictors. Model 2 was compared to Model 1 (established
risk factors only; Table 3). Model 1, which includes NT-proBNP,
has a fair-to-good predictive ability (C-index 0.785, 95% CI
0.754–0.816). The addition of phenylalanine and acetate (Model 2)
did not significantly improve the predictive ability (C-index 0.787,
95% CI 0.758–0.819; change in C-index 0.0036, 95% CI –0.046
to 0.051; P= 0.880). However, the net reclassification index (NRI)
demonstrated that Model 2 improved classification of participants
who did not experience HFH to more appropriate risk categories
in both categorical and continuous models (categorical NRI for
non-cases 0.010, 95% CI 0.001–0.019; P= 0.012; continuous NRI
for non-cases 0.143, 95% CI 0.115–0.170; P< 0.001). Only the
overall continuous NRI showed an improvement with Model 2
compared to Model 1 (0.205, 95% CI 0.055–0.355; P= 0.007).
External replication: FINRISK 1997
cohort
In the FINRISK 1997 cohort, 24 out of 85 metabolic measures (as
quantified by NMR metabolomics) were significantly associated
with 5-year incident HF risk (P< 0.05) (supplementary material
online, Table S3). Six measures were inversely associated with HF
[ratio of omega-6 fatty acids to total fatty acids, ratio of polyunsat-
urated fatty acids (PUFA) to total fatty acids, HDL2-cholesterol,
ratio of linoleic acid to total fatty acids, 3-hydroxybutyrate and
LDL-cholesterol), and 18 were positively associated with HF
[monounsaturated fatty acid (MUFA) to total fatty acid ratio,
pyruvate, HDL-triglycerides, isoleucine, total triglycerides, MUFA,
tyrosine, mean very low-density lipoprotein (VLDL) diameter,
phenylalanine, lactate, alanine, glycoprotein acetyls, glucose,
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Demographic characteristics: incident heart failure hospitalisation (HFH) vs. no HFH in PROSPER
Characteristic No HFH (n= 5159) HFH (n=182) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 75.78± 3.34 76.66± 3.55 <0.001
Male sex 2480 (48.1) 108 (59.3) 0.003
Current smoker 1289 (25.0) 43 (23.8) 0.70
Country
Scotland 2217 (43.0) 88 (48.4) 0.004
Ireland 1920 (37.2) 76 (41.8)
The Netherlands 1022 (19.8) 18 (9.9)
BMI, kg/m2 26.57± 4.18 27.05± 4.16 0.10
Myocardial infarction 705 (13.7) 53 (29.3) <0.001
SBP 154.97± 21.95 155.22± 22.78 0.67
DBP 85.02±11.01 82.44± 11.56 0.005
CABG 141 (2.7) 4 (2.2) 0.66
PTCA 93 (1.8) 3 (1.6) 0.88
TIA 400 (7.8) 16 (8.8) 0.61
Stroke 202 (3.9) 12 (6.6) 0.07
Angina 1289 (25.0) 80 (44.0) <0.001
Claudication 334 (6.5) 26 (14.3) <0.001
PVD surgery 107 (2.1) 5 (2.7) 0.53
ACE inhibitors 920 (17.8) 59 (30.8) <0.001
Beta-blockers 1333 (25.8) 40 (22.0) 0.24
Calcium channel blockers 1286 (24.9) 56 (30.8) 0.07
Anti-arrhythmics 124 (2.4) 10 (5.5) 0.009
Diuretics 2060 (39.9) 85 (46.7) 0.07
Diabetes 360 (7.0) 18 (9.9) 0.13
eGFR, mL/min/1.73m2 60.36±14.55 56.63± 15.37 <0.001
Treatment group (pravastatin) 2564 (49.7) 85 (47.6) 0.43
6-month NT-proBNP, ng/L 143.1 (77.9–274.7) 522.9 (215.8–1144.0) <0.001
Demographic characteristics are detailed for 5341 individuals with metabolic measures quantified by nuclear magnetic resonance spectroscopy. Baseline (or 6-month for
NT-proBNP) summary characteristics are reported as means ± standard deviation for continuous measures, with the exception of NT-proBNP concentration which was not
normally distributed (median, IQR), and as numbers with percentage for categorical variables. Measures that are significantly different between those later hospitalised for HF
vs. those who were not are shown in bold (P< 0.05). Any missing data at 6months was imputed from 0months.
ACE, angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass graft; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HF,
heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease; SBP, systolic
blood pressure; TIA, transient ischaemic attack.
VLDL-triglyceride, triglyceride ratio to phosphoglycerides, inter-
mediate density lipoprotein (IDL)-triglyceride, LDL-triglyceride,
and IDL-phospholipid concentration]. The strongest predictor
of HF in PROSPER, phenylalanine, was replicated in FINRISK
(HR 1.23 for one SD increase, 95% CI 1.03–1.48; P= 0.023).
The association of acetate was not replicated (HR 1.0, 95% CI
0.842–1.19; P= 0.99). Estimated HRs were visually compared
between PROSPER and FINRISK (Figure 3). This comparison
demonstrates that HRs for a number of other metabolites for
incident HF appear stronger in a middle-aged cohort (derived from
the general population) compared to an elderly cohort (recruited
with pre-existing CVD or at high risk of CVD22).
Discussion
We report that in PROSPER, 13 metabolites and lipoprotein mea-
sures were associated with HFH but only phenylalanine (positively)
and acetate (inversely) were independently associated with HFH
after adjustment for classical risk factors inclusive of NT-proBNP. .
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. These two metabolites only moderately improved prediction of
HFH (no significant improvement in C-index) with slight improve-
ment in the net reclassification on non-cases (i.e. improved
specificity). However, the pathways underlying the metabolite asso-
ciations with HFH are arguably more interesting, suggesting novel
insights into the development of HF, which is known to be mecha-
nistically entwined with functional metabolic changes, such as gly-
colysis, gluconeogenesis and lipolysis.11 The improvement in over-
all continuous NRI, especially net reclassification of non-cases, is
potentially important. The final model correctly down-classified
non-cases, potentially reducing the burden on echocardiography
facilities and increasing the positive value of echocardiography with-
out a statistically significant net reclassification of cases (no signifi-
cant increase in the number of cases not referred for echocardio-
graphy, i.e. missed).
In this study, of the multiple metabolites measured in the elderly,
phenylalanine had the strongest association with incident HFH
(HR 1.29 per log SD increase, 95% CI 1.10–1.53; P= 0.002).
Notably, raised phenylalanine concentration has been identified in
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Metabolic measures quantified by nuclear magnetic resonance metabolomics in heart failure hospitalisation
(HFH) vs. no HFH in PROSPER
Metabolite or lipoprotein measure No HFH (n= 5159) HFH (n=182) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Apolipoprotein A1 (g/L) 1.54 (1.44–1.65) 1.49 (1.40–1.60) <0.001
Concentration of medium HDL particles (nmol/L) 1.77 (1.59–1.97) 1.64 (1.48–1.88) <0.001
Concentration of small HDL particles (nmol/L) 4.40 (4.17–4.66) 4.30 (3.99–4.58) <0.001
Creatinine (𝜇mol/L) 71.00 (60.50–82.90) 76.70 (64.10–96.10) <0.001
Glycoprotein acetyls (mmol/L) 1.27 (1.18–1.38) 1.32 (1.22–1.42) <0.001
Phenylalanine (mmol/L) 45.10 (40.70–49.80) 47.85 (43.30–52.40) <0.001
Phospholipids in HDL (𝜇mol/L) 1.32 (1.16–1.52) 1.25 (1.10–1.44) <0.001
Esterified cholesterol (%) 71.35 (70.05–72.55) 70.94 (69.44–72.00) 0.001
Mean diameter for LDL particles (nm) 23.70 (23.60–23.70) 23.70 (23.60–23.70) 0.002
Total cholesterol in HDL2 (mmol/L) 0.83 (0.68–1.03) 0.76 (0.64–0.95) 0.003
Total cholesterol in HDL (mmol/L) 1.31 (1.14–1.50) 1.24 (1.10–1.44) 0.004
3-Hydroxybutyrate (mmol/L) 0.10 (0.07–0.15) 0.12 (0.08–0.17) 0.011
Total phospholipids (𝜇mol/L) 2.65 (2.41–2.90) 2.59 (2.34–2.87) 0.014
Citrate (𝜇mol/l) 96.80 (81.40–112.00) 99.85 (85.10–117.00) 0.032
Ratio of omega-3 fatty acids to total fatty acids 3.81 (3.35–4.42) 3.64 (3.29–4.23) 0.033
Concentration of large HDL particles (nmol/L) 1.00 (0.76–1.29) 0.92 (0.70–1.21) 0.034
Lactate (mmol/L) 2.33 (1.80–3.39) 2.44 (1.94–3.84) 0.04
Acetate (mmol/L) 0.03 (0.02–0.03) 0.02 (0.02–0.03) 0.046
Values are expressed as median and interquartile range. Only metabolite and lipoprotein measures that are significantly different between HFH vs. no HFH are shown (P< 0.05)
(see supplementary material online, Table S1, for metabolite and lipoprotein measures not significantly different between HFH and no HFH). Measures shown in order of
ascending P-value; those ≤0.014 are shown in bold, notionally significant after correcting for false discovery using the Benjamini and Hochberg method and a false discovery
rate of 0.1.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
cross-sectional studies comparing individuals with established HF
to normal controls.12,15,17,33,34 However, to our knowledge, ours
is the first study to suggest phenylalanine also predicts incident
HFH. A similar association was observed in the external replica-
tion cohort, despite their substantial differences in age (FINRISK
population being much younger) and co-morbidities (far fewer in
FINRISK), and consequently different HF risk profiles. The con-
sistency in this association is therefore useful to see, particularly
given that risk factor associations with adverse outcomes, such
as HF, typically weaken in older cohorts (as observed for blood
pressure,35 adiponectin,36 and cholesterol23,37). Phenylalanine is an
essential amino acid and a precursor for tyrosine. The ability of
increased phenylalanine to predict incident HFH may indicate sev-
eral potential mechanisms. Firstly, it may reflect early altered pro-
tein catabolism.10,12,33 Increased phenylalanine may originate from
both cardiac and/or skeletal muscles, perhaps due to shared under-
lying pathogenesis or skeletal muscle degradation resulting from
reduced tissue blood supply in individuals with HF.17 Increased pro-
tein catabolism may also be a result of insulin resistance, a putative
risk factor for HF.27,33 Secondly, increased phenylalanine concentra-
tions may reflect impaired uptake and utilisation of amino acids,15
impaired renal function,38 or impaired liver function with decreased
phenylalanine hydroxylation.12 Thirdly, they may indicate depletion
of tetrahydrobiopterin (a co-factor for phenylalanine hydroxylase
which converts phenylalanine to tyrosine), resulting from induc-
tion of nitric oxide synthase-2, for which tetrahydrobiopterin is
also a co-factor.12 Finally, it is known that phenylalanine and tyro-
sine are precursors of catecholamines, including adrenaline and .
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.. noradrenaline, and higher concentrations are observed in HF due
to stress response to reduced cardiac output.33 Clearly, further
mechanistic studies are needed to determine why phenylalanine
is predictive for HF and whether this association could poten-
tially be causal in nature. Of note, phenylalanine has been iden-
tified as one of four novel NMR-determined metabolites asso-
ciated with incident CVD events in the FINRISK 1997 popula-
tion (and validated in the SABRE and BWHHS population) using
the same NMR metabolomics platform,27 so that its associa-
tion with CVD risk may suggest common pathways to cardiac
damage.
Acetate was inversely associated with HF (HR 0.81 for one
SD increase, 95% CI 0.68–0.98, P= 0.026). This may indicate
alteration in glycolysis, fatty acid and/or amino acid metabolism,
dietary effects, or microbiome effects.39 Increased urinary acetic
acid has been observed in patients with established HF.40 However,
this observation was not replicated in FINRISK, although the
differences between the cohorts must be emphasised: difference
in age (24 to 74 in FINRISK vs. 70 to 82 in PROSPER); difference
in event rate (3.4% at 3 years in PROSPER vs. 1.8% at 5 years in
FINRISK); and likely differences in diet and lifestyle.
Measures of HDL, such as apolipoprotein A1, concentration
of medium and small HDL particles and the phospholipid and
cholesterol content of HDL were found to be slightly lower
in those who subsequently suffered HFH vs. those who did
not, although their associations were attenuated in multivariable
models. Neither HDL-cholesterol nor HDL-cholesterol to
total cholesterol ratio have been consistently related to risk
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Forest plot of hazard ratios and 95% confidence intervals (CI) of association for metabolites with incident heart failure hospitalisation
(HFH) in PROSPER during 2.7 years of follow-up. Associations were adjusted for treatment group, age, sex, smoking status, country, body
mass index (BMI), myocardial infarction, systolic (SBP) and diastolic blood pressure (DBP), coronary artery bypass graft, percutaneous
transluminal coronary angioplasty, transient ischaemic attack, stroke, angina, claudication, peripheral vascular disease, diabetes, estimated
glomerular filtration rate (eGFR), N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration (6-month) and treatment with
angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers, anti-arrhythmics and diuretics (note all medications are
as recorded at baseline, 0month). Nuclear magnetic resonance measures with P< 0.05 in Model A are shown. HDL, high-density lipoprotein;
LDL, low-density lipoprotein. Model A: adjusted for sex, BMI, SBP, DBP, current smoking, diabetes, pravastatin/placebo, blood pressure-lowering
therapy, major coronary events/baseline cardiovascular disease. Model B: adjusted as for Model A plus eGFR. Model C: adjusted as for Model
B plus NT-proBNP.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Risk prediction metric values for incident heart failure hospitalisation in PROSPER
Metric point estimate (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Established risk factors (Model 1)
C-index (95% CI) 0.785 (0.754–0.816)
Established risk factors plus phenylalanine and acetate (Model 2)
C-index (95% CI) 0.787 (0.758–0.819)
Gain in predictive ability in Model 2 vs. 1
C-index change 0.0036 (–0.0457 to 0.0505) 0.880
Categorical NRI of 3-year risk
Cases 0.0000 (–0.0470 to 0.0470) 0.500
Non-cases 0.0104 (0.0014–0.0194) 0.012
Overall 0.0104 (–0.0374 to 0.0582) 0.670
Continuous NRI of 3-year risk
Cases 0.0621 (–0.0849 to 0.2092) 0.408
Non-cases 0.1429 (0.1155–0.1703) <0.001
Overall 0.2051 (0.0555–0.3546) 0.007
Model 1 (established risk factors, including NT-proBNP) and Model 2 (established risk factors plus phenylalanine and acetate) have a fair-to-good C-index value. Adding
phenylalanine and acetate to usual risk factors (including NT-proBNP) did not significantly improve the C-index. It did improve prediction of non-cases (statistically significant
improvement in categorical and continuous NRI).
CI, confidence interval; NRI, net reclassification index.
of incident HF.23,32 Our results broadly agree with other stud-
ies suggesting HDL-cholesterol per se is not a useful early
predictor of HF.23
Fatty acids provide the majority of energy substrates required
by the heart.20 It is thought that HF may develop when fatty acids
cannot be adequately utilised to meet the energy needs of the
heart.18 We did not observe any significant associations between
NMR measures of fatty acids with HFH in PROSPER, in contrast to
the results from FINRISK. In FINRISK, a number of lipid measures
(including ratio of MUFA, PUFA and omega-6 fatty acid to total
fatty acid) were associated with HF, some with stronger HRs than
phenylalanine. Again, differences between the cohorts must be
emphasised, and clearly further cohorts are needed to test our
findings.
Our study has some notable strengths beyond the testing of
biomarker concentrations in two cohorts. This is a compara-
tively large study for metabolic profiling and is made possible by
high-throughput automated NMR metabolomics.21 This method
also allowed quantification of lipids and detailed lipoprotein analysis
in addition to metabolites.21 Additionally, we were careful to adjust
for NT-proBNP in both cohorts, a robust predictor of incident HF.
We accept some limitations. Our endpoint was based on hospital-
isation for HF in PROSPER, and the decision for whether to admit
a patient for HF is not standardised. Patients who developed HF
without being hospitalised (milder episodes of HF) will be missed
in our study, although mild episodes of HF in older age are less clin-
ically concerning if they do not later cause hospitalisation for symp-
toms. There was no interaction for main effects reported here by
trial treatment groups. Individuals with congestive HF (NYHA class
III and IV) were excluded at baseline, however some patients with
HF may be present in the non-HF group at 6months (the baseline
for this study due to sample availability). About 25% of non-HF
individuals had a 6-month NT-proBNP concentration of 274 ng/L, .
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.. above the 125 ng/L rule-out value recommended in the Euro-
pean Society of Cardiology guidelines (negative predictive value
0.94–0.98; positive predictive value 0.44–0.57).41 However, sug-
gested rule-in values for 50–70 and >75 year olds are 900 ng/L and
1800 ng/L, respectively.42 Information was not available to differen-
tiate diagnosis of HF with preserved ejection fraction (HFpEF) or
HF with reduced ejection fraction (HFrEF), and associations may be
different for these HF categories due to differing pathogenesis.6,19
The definition of HF used in this study may bias prediction of
HFrEF hospitalisation; however, a recent study reported little dif-
ference in number of hospitalisations for HFpEF vs. HFrEF, particu-
larly in the Caucasian and over 75-year age groups.43 Additionally,
patients were not stratified by acute vs. chronic HF, ischaemic vs.
non-ischaemic HF; again associations may differ within these sub-
groups. Finally, samples from PROSPER and FINRISK were about
20 years old at time of NMR spectroscopy, therefore there may
be degradation of some metabolic measures. However, since cases
and controls were treated the same way, identified differences are
robust.
In conclusion, we have demonstrated that elevated phenylalanine
concentrations were reproducibly and independently associated
with incident HFH. However, since addition of phenylalanine and
acetate to the model did not improve HF prediction beyond
established clinical predictors and NT-proBNP, the clinical utility
is likely to be low. It is possible that more detailed phenotyping
available using MSmetabolomics may identify more robust markers;
however, this method provides only relative quantitation (generally)
and is relatively expensive, limiting the number of samples that
can be analysed. It is also possible that 1H-NMR metabolomics of
specific subtypes of HF may identify useful biomarkers for those
patients. Additionally, the mechanistic pathways that lead to raised
phenylalanine concentrations preceding clinical presentation with
HF are of interest.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Comparison of hazard ratios for incident heart failure hospitalisation or heart failure events in PROSPER and the FINRISK 1997
cohort. Hazard ratios are adjusted for age, sex, body mass index, systolic and diastolic blood pressure, current smoking, diabetes, pravastatin/
placebo (in PROSPER); blood pressure-lowering therapy, major coronary events/baseline cardiovascular disease; estimated glomerular filtration
rate and N-terminal pro-B-type natriuretic peptide. Only metabolic measures with P< 0.01 in at least one cohort are displayed (with the
exception of acetate). CI, confidence interval; FA, fatty acid; HDL, high-density lipoprotein; LA, linoleic acid; MUFA, monounsaturated fatty
acid; PUFA, polyunsaturated fatty acid.
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